Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.

Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R.

Int J Gynecol Cancer. 2016 Jan;26(1):43-51. doi: 10.1097/IGC.0000000000000586.

2.

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.

Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, Zwirner M.

Int J Gynecol Cancer. 2005 Sep-Oct;15(5):679-91.

PMID:
16174214
3.

Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.

Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.

Gynecol Oncol. 2012 Nov;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. Epub 2012 Jul 24.

PMID:
22835718
4.

New tumor markers: CA125 and beyond.

Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K.

Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81. Review.

PMID:
16343244
5.

HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.

Richards A, Herbst U, Manalang J, Pather S, Saidi S, Tejada-Berges T, Tan K, Williams P, Carter J.

Aust N Z J Obstet Gynaecol. 2015 Oct;55(5):493-7. doi: 10.1111/ajo.12363. Epub 2015 Jul 14.

PMID:
26172511
6.

Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.

Cho HY, Park SH, Park YH, Kim HB, Kang JB, Hong SH, Kyung MS.

J Korean Med Sci. 2015 Dec;30(12):1777-83. doi: 10.3346/jkms.2015.30.12.1777. Epub 2015 Nov 30.

7.

A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.

Lycke M, Kristjansdottir B, Sundfeldt K.

Gynecol Oncol. 2018 Oct;151(1):159-165. doi: 10.1016/j.ygyno.2018.08.025. Epub 2018 Aug 24.

PMID:
30149898
8.

Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.

Robati M, Ghaderi A, Mehraban M, Shafizad A, Nasrolahi H, Mohammadianpanah M.

Arch Gynecol Obstet. 2013 Oct;288(4):859-65. doi: 10.1007/s00404-013-2819-7. Epub 2013 Apr 7.

PMID:
23564055
9.

HE4 in the differential diagnosis of ovarian masses.

Granato T, Porpora MG, Longo F, Angeloni A, Manganaro L, Anastasi E.

Clin Chim Acta. 2015 Jun 15;446:147-55. doi: 10.1016/j.cca.2015.03.047. Epub 2015 Apr 16. Review.

PMID:
25892674
10.
11.

Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.

Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, Tognon G, Bignotti E, Tassi RA, Odicino F, Caimi L, Sartori E, Santin AD, Pecorelli S, Ravaggi A.

Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2496-506. doi: 10.1158/1055-9965.EPI-11-0635. Epub 2011 Oct 25.

12.

Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.

Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel Ghaffar HM.

Diagn Pathol. 2013 Jan 23;8:11. doi: 10.1186/1746-1596-8-11.

13.

Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.

Fujiwara H, Suzuki M, Takeshima N, Takizawa K, Kimura E, Nakanishi T, Yamada K, Takano H, Sasaki H, Koyama K, Ochiai K.

Tumour Biol. 2015 Feb;36(2):1045-53. doi: 10.1007/s13277-014-2738-7. Epub 2014 Oct 19.

14.

HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.

Romagnolo C, Leon AE, Fabricio ASC, Taborelli M, Polesel J, Del Pup L, Steffan A, Cervo S, Ravaggi A, Zanotti L, Bandiera E, Odicino FE, Scattolo N, Squarcina E, Papadakis C, Maggino T, Gion M.

Gynecol Oncol. 2016 May;141(2):303-311. doi: 10.1016/j.ygyno.2016.01.016. Epub 2016 Jan 19.

PMID:
26801941
15.

Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses?

Yoshida A, Derchain SF, Pitta DR, Crozatti N, Andrade LALA, da Silva RF, Sarian LO.

Int J Biol Markers. 2017 Mar 2;32(1):e83-e89. doi: 10.5301/jbm.5000226.

PMID:
27516000
16.

Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.

Gąsiorowska E, Michalak M, Warchoł W, Lemańska A, Jasiński P, Spaczyński M, Nowak-Markwitz E.

Ginekol Pol. 2015 Feb;86(2):88-93.

PMID:
25807831
17.

Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.

Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, Lu KH, Bast RC Jr.

Gynecol Oncol. 2011 Sep;122(3):548-53. doi: 10.1016/j.ygyno.2011.06.002. Epub 2011 Jun 25.

18.

The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?

Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, Salvagno GL, Franchi M, Lippi G, Guidi GC.

Clin Chem Lab Med. 2011 Mar;49(3):521-5. doi: 10.1515/CCLM.2011.075. Epub 2011 Feb 3.

PMID:
21288178
19.

Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.

Fawzy A, Mohamed MR, Ali MA, Abd El-Magied MH, Helal AM.

Asian Pac J Cancer Prev. 2016;17(1):323-33.

20.

Supplemental Content

Support Center